Stockreport

Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Following positive results from its SURMOUNT-5 trial, Eli Lilly's Zepbound (tirzepatide) will surpass Novo Nordisk's Weogvy (semaglutide) in the obesity treatment marke [Read more]